Business
GSK Acquires Nuvalent for Cancer Drugs
GlaxoSmithKline (GSK) is acquiring Nuvalent, a maker of targeted cancer drugs, for $10.6 billion. This acquisition bolsters GSK's portfolio in biopharma.
Coverage timeline — 1 article
STAT News
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
2026-06-09 06:48 UTC